These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 11485510)

  • 1. Diabetes and depot medroxyprogesterone contraception in Navajo women.
    Kim C; Seidel KW; Begier EA; Kwok YS
    Arch Intern Med; 2001 Jul; 161(14):1766-71. PubMed ID: 11485510
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bone density in women receiving depot medroxyprogesterone acetate for contraception.
    Cundy T; Evans M; Roberts H; Wattie D; Ames R; Reid IR
    BMJ; 1991 Jul; 303(6793):13-6. PubMed ID: 1830502
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Establishing the minimum effective dose and additive effects of depot progestin in suppression of human spermatogenesis by a testosterone depot.
    Handelsman DJ; Conway AJ; Howe CJ; Turner L; Mackey MA
    J Clin Endocrinol Metab; 1996 Nov; 81(11):4113-21. PubMed ID: 8923869
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of hormonal contraception on bone mineral density after 24 months of use.
    Berenson AB; Breitkopf CR; Grady JJ; Rickert VI; Thomas A
    Obstet Gynecol; 2004 May; 103(5 Pt 1):899-906. PubMed ID: 15121563
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Food and Drug Administration and medroxyprogesterone acetate. What are the issues?
    Rosenfield A; Maine D; Rochat R; Shelton J; Hatcher RA
    JAMA; 1983 Jun; 249(21):2922-8. PubMed ID: 6221125
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A prospective comparison of bone density in adolescent girls receiving depot medroxyprogesterone acetate (Depo-Provera), levonorgestrel (Norplant), or oral contraceptives.
    Cromer BA; Blair JM; Mahan JD; Zibners L; Naumovski Z
    J Pediatr; 1996 Nov; 129(5):671-6. PubMed ID: 8917232
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Steroidal contraceptives and bone fractures in women: evidence from observational studies.
    Lopez LM; Chen M; Mullins S; Curtis KM; Helmerhorst FM
    Cochrane Database Syst Rev; 2012 Aug; (8):CD009849. PubMed ID: 22895991
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cervical cancer risk and use of depot-medroxyprogesterone acetate in Costa Rica.
    Oberle MW; Rosero-Bixby L; Irwin KL; Fortney JA; Lee NC; Whatley AS; Bonhomme MG
    Int J Epidemiol; 1988 Dec; 17(4):718-23. PubMed ID: 2976059
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Depot medroxyprogesterone acetate versus an oral contraceptive combined with very-low-dose danazol for long-term treatment of pelvic pain associated with endometriosis.
    Vercellini P; De Giorgi O; Oldani S; Cortesi I; Panazza S; Crosignani PG
    Am J Obstet Gynecol; 1996 Aug; 175(2):396-401. PubMed ID: 8765259
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Forearm bone density in users of Depo-Provera as a contraceptive method.
    Bahamondes L; Perrotti M; Castro S; Faúndes D; Petta C; Bedone A
    Fertil Steril; 1999 May; 71(5):849-52. PubMed ID: 10231044
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Population-based study of risk of venous thromboembolism associated with various oral contraceptives.
    Farmer RD; Lawrenson RA; Thompson CR; Kennedy JG; Hambleton IR
    Lancet; 1997 Jan; 349(9045):83-8. PubMed ID: 8996419
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nondaily hormonal contraception: establishing a fit between product characteristics and patient preferences.
    Levine JP
    J Fam Pract; 2004 Nov; 53(11):904-13. PubMed ID: 15527729
    [No Abstract]   [Full Text] [Related]  

  • 13. Depot medroxyprogesterone acetate contraception in women with medical problems.
    Frederiksen MC
    J Reprod Med; 1996 May; 41(5 Suppl):414-8. PubMed ID: 8725704
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Breast cancer among young U.S. women in relation to oral contraceptive use.
    White E; Malone KE; Weiss NS; Daling JR
    J Natl Cancer Inst; 1994 Apr; 86(7):505-14. PubMed ID: 8133534
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes in mammographic densities induced by a hormonal contraceptive designed to reduce breast cancer risk.
    Spicer DV; Ursin G; Parisky YR; Pearce JG; Shoupe D; Pike A; Pike MC
    J Natl Cancer Inst; 1994 Mar; 86(6):431-6. PubMed ID: 8120917
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A case-control study of breast cancer and hormonal contraception in Costa Rica.
    Lee NC; Rosero-Bixby L; Oberle MW; Grimaldo C; Whatley AS; Rovira EZ
    J Natl Cancer Inst; 1987 Dec; 79(6):1247-54. PubMed ID: 2961909
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Weight gain in obese and nonobese adolescent girls initiating depot medroxyprogesterone, oral contraceptive pills, or no hormonal contraceptive method.
    Bonny AE; Ziegler J; Harvey R; Debanne SM; Secic M; Cromer BA
    Arch Pediatr Adolesc Med; 2006 Jan; 160(1):40-5. PubMed ID: 16389209
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Parenteral contraceptive drugs: depot progestins].
    Rabe T; Runnebaum B
    Wien Med Wochenschr; 1987 Nov; 137(20-21):474-9. PubMed ID: 2967589
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Return of fertility after discontinuation of depot medroxyprogesterone acetate and intra-uterine devices in Northern Thailand.
    Pardthaisong T; Gray RH; McDaniel EB
    Lancet; 1980 Mar; 1(8167):509-12. PubMed ID: 6102234
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of low-dose oral contraceptives and stroke in young women.
    Schwartz SM; Siscovick DS; Longstreth WT; Psaty BM; Beverly RK; Raghunathan TE; Lin D; Koepsell TD
    Ann Intern Med; 1997 Oct; 127(8 Pt 1):596-603. PubMed ID: 9341057
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.